Abcellera Biologics Inc Market Cap ($3.53 Billion)
Market Cap & Net Worth: Abcellera Biologics Inc (ABCL)
Abcellera Biologics Inc market cap. Abcellera Biologics Inc (NASDAQ:ABCL) has a market capitalization of $3.53 Billion ($3.53 Billion) as of October 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4327 globally and #1517 in its home market, demonstrating a 6.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abcellera Biologics Inc's stock price $13.08 by its total outstanding shares 324047363 (324.05 Million).
Abcellera Biologics Inc Market Cap History (2020–2026)
Abcellera Biologics Inc market cap history from 2020 to 2026. Data shows change from $13.04 Billion to $4.24 Billion (-22.56% CAGR). Check today's stock price for Abcellera Biologics Inc for real-time trading data and today's change.
Index Memberships
Abcellera Biologics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.13% | #116 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.01% | #504 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.19% | #74 of 263 |
Weight: Abcellera Biologics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abcellera Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abcellera Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Abcellera Biologics Inc (ABCL) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
14.75x
Abcellera Biologics Inc's market cap is 14.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $13.04 Billion | $233.16 Million | $118.92 Million | 55.93x | 109.65x |
| 2021 | $4.63 Billion | $11.61 Million | -$2.21 Million | 399.08x | N/A |
| 2022 | $3.28 Billion | $485.42 Million | $158.52 Million | 6.76x | 20.71x |
| 2023 | $1.85 Billion | $38.02 Million | -$146.40 Million | 48.66x | N/A |
| 2024 | $949.46 Million | $28.83 Million | -$162.86 Million | 32.93x | N/A |
| 2025 | $1.11 Billion | $75.13 Million | -$146.41 Million | 14.75x | N/A |
Competitor Companies of ABCL by Market Capitalization
Companies near Abcellera Biologics Inc in the global market cap rankings as of October 30, 2026. See net asset quality index of Abcellera Biologics Inc to understand what proportion of total assets are financed by equity.
Key companies related to Abcellera Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Abcellera Biologics Inc (2020–2026)
Market capitalization of Abcellera Biologics Inc from 2020 to today. Between 2020 and today, Abcellera Biologics Inc's market cap moved from $13.04 Billion to $ 4.24 Billion, with a yearly change of -22.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.24 Billion | +282.46% |
| 2025 | $1.11 Billion | +16.72% |
| 2024 | $949.46 Million | -48.69% |
| 2023 | $1.85 Billion | -43.63% |
| 2022 | $3.28 Billion | -29.16% |
| 2021 | $4.63 Billion | -64.46% |
| 2020 | $13.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Abcellera Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.53 Billion USD |
| MoneyControl | $3.53 Billion USD |
| MarketWatch | $3.53 Billion USD |
| marketcap.company | $3.53 Billion USD |
| Reuters | $3.53 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more